Basal Cell Carcinoma

  • Manisha J PatelEmail author
  • Phillip M Williford
  • Stephen Shumack

Core Messages

  • Basal cell carcinoma (BCC) is the most common human cancer.

  • The most significant environmental carcinogen for BCC is ultraviolet light (UVL) exposure.

  • Clinical pathological correlation is essential in choosing the appropriate treatment for the various subtypes of BCC.

  • Untreated BCC or inappropriately managed BCC can cause significant morbidity and even mortality.

  • The mainstay of treatment has focused on the total removal (excision) or mechanical destruction of the tumor.

  • New treatment modalities include immune modulators, topical photodynamic therapy (PDT), and drugs targeting genetic defects.

  • Education on skin cancer prevention should target all age groups.


Basal Cell Carcinoma National Comprehensive Cancer Network National Comprehensive Cancer Network Xeroderma Pigmentosum Nonmelanoma Skin Cancer 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


  1. 1.
    Hayes RC, Leonfellner S, Pilgrim W, Liu J, Keeling DN (2007) Incidence of nonmelanoma skin cancer in New Brunswick, Canada, 1992 to 2001. J Cutan Med Surg 11:45 –52PubMedGoogle Scholar
  2. 2.
    Ko CB, Walton S, Keczkes K, Bury HP, Nicholson C (1994) The emerging epidemic of skin cancer. Br J Dermatol 130:269 –272PubMedCrossRefGoogle Scholar
  3. 3.
    Marks R, Staples M, Giles GG (1993) Trends in non-mel-anocytic skin cancer treated in Australia: the second national survey. Int J Cancer 53:585 –590PubMedCrossRefGoogle Scholar
  4. 4.
    Miller DL, Weinstock MA (1994) Nonmelanoma skin cancer in the United States: incidence. J Am Acad Dermatol 30:774 –778PubMedCrossRefGoogle Scholar
  5. 5.
    Gilbody JS, Aitken J, Green A (1994) What causes basal cell carcinoma to be the commonest cancer? Aust J Public Health 18:218 –221PubMedCrossRefGoogle Scholar
  6. 6.
    Miller SJ (1991) Biology of basal cell carcinoma (Part I). J Am Acad Dermatol 24:1 –13PubMedCrossRefGoogle Scholar
  7. 7.
    Stern R (2007) The mysteries of geographic variability in nonmelanoma skin cancer incidence. Arch Dermatol 135:843 –844CrossRefGoogle Scholar
  8. 8.
    American Cancer Society Facts and Figures. American Cancer Society. 1 –1 –2008Google Scholar
  9. 9.
    Lear W, Dahlke E, Murray CA (2007) Basal cell carcinoma: review of epidemiology, pathogenesis, and associated risk factors. J Cutan Med Surg 11:19 –30PubMedGoogle Scholar
  10. 10.
    Scrivener Y, Grosshans E, Cribier B (2002) Variations of basal cell carcinomas according to gender, age, location and histopathological subtype. Br J Dermatol 147:41 –47PubMedCrossRefGoogle Scholar
  11. 11.
    Mikhail GR, Nims LP, Kelly AP Jr, Ditmars DM Jr, Eyler WR (1977) Metastatic basal cell carcinoma: review, pathogenesis, and report of two cases. Arch Dermatol 113:1261 –1269PubMedCrossRefGoogle Scholar
  12. 12.
    von DH, Stevens PJ (1984) Metastatic basal cell carcinoma. Report of five cases and review of 170 cases in the literature. J Am Acad Dermatol 10:1043 –1060PubMedCrossRefGoogle Scholar
  13. 13.
    Affleck AG, Gore A, Millard LG, Perks, AGD, Kulkarni K, Chan S (2007) Giant primary basal cell carcinoma with fatal hepatic metastases. JEADV 21:262 –263PubMedGoogle Scholar
  14. 14.
    Lo JS, Sow SN, Reizner GT, et al (1991) Metastic basal cell carcinoma: a report of twelve cases with a review of the literature. J Am Acad Dermatol 24:715 –718PubMedCrossRefGoogle Scholar
  15. 15.
    Robinson, JK, Dahiya M (2003) Basal cell carcinoma with pulmonary and lymph node metastasis causing death. Arch Dermatol 139:643 –648CrossRefGoogle Scholar
  16. 16.
    Sahl WJ, Snow SN, Levine NS (1994) Giant basal cell carcinoma. Report of two cases and review of the literature. J Am Acad Dermatol 30:856 –859CrossRefGoogle Scholar
  17. 17.
    Fears TR, Scotto J, Schneiderman MA (1977) Mathematical models of age and ultraviolet effects on the incidence of skin cancer among whites in the United States. Am J Epidemiol 105:420 –427PubMedGoogle Scholar
  18. 18.
    Harris RB, Griffith K, Moon TE (2001) Trends in the incidence of nonmelanoma skin cancers in southeastern Arizona, 1985 –1996. J Am Acad Dermatol 45:528 –536PubMedCrossRefGoogle Scholar
  19. 19.
    Hoy WE (1996) Nonmelanoma skin carcinoma in Albuquerque, New Mexico: experience of a major health care provider. Cancer 77:2489 –2495PubMedCrossRefGoogle Scholar
  20. 20.
    Marshall DR (1968) The clinical and pathological effects of prolonged solar exposure. II: the association with basal cell carcinoma. Aust N Z J Surg 38:89 –97PubMedGoogle Scholar
  21. 21.
    Oettle AG (1963) Skin cancer in Africa. Natl Cancer Inst Monogr 10:197Google Scholar
  22. 22.
    Quisenberry WB (1963) Ethnic difference in skin cancer in Hawaii. Natl Cancer Inst Monogr 10:181Google Scholar
  23. 23.
    Ten Seldam REJ (1963) Skin cancer in Australia. Natl Cancer Inst Monogr 10:153Google Scholar
  24. 24.
    Vitaliano PP, Urbach F (1980) The relative importance of risk factors in nonmelanoma carcinoma. Arch Dermatol 16:454 –456CrossRefGoogle Scholar
  25. 25.
    Alexander GA, Henschke UK (1981) Advanced skin cancer in Tanzanian albinos: preliminary observations. J Natl Med Assoc 73:1047 –1054PubMedGoogle Scholar
  26. 26.
    Keeler EE (1963) Albinism, zeroderma pigmentosum and skin cancer. Natl Cancer Inst Monogr 10:349Google Scholar
  27. 27.
    Okoro AN (1975) Albinism in Nigeria. A clinical and social study. Br J Dermatol 92:485 –492PubMedCrossRefGoogle Scholar
  28. 28.
    Beckenstein MS, Windle BH (1995) Basal cell carcinoma in black patients: the need to include it in the differential diagnosis. Ann Plast Surg 35:546 –548PubMedCrossRefGoogle Scholar
  29. 29.
    Fleming ID, Barnwell JR, Burleson PE, et al (1975) Skin cancer in black patients. Cancer 35:600 –605PubMedCrossRefGoogle Scholar
  30. 30.
    Mora RG, Burris R (1981) Cancer of the skin in blacks: a review of 128 patients with basal-cell carcinoma. Cancer 47:1436 –1438PubMedCrossRefGoogle Scholar
  31. 31.
    Fears TR, Scotto J (1983) Estimating increases in skin cancer morbidity due to increases in ultraviolet radiation exposure. Cancer Invest 1:119 –126PubMedCrossRefGoogle Scholar
  32. 32.
    Ziegler A, Leffell DJ, Kunala S, Sharma HW, Gailani M, Simon JA, Halperin AJ, Baden HP, Shapiro PE, Bale AE (1993) Mutation hotspots due to sunlight in the p53 gene of nonmelanoma skin cancers. Proc Natl Acad Sci USA 90:4216 –4220PubMedCrossRefGoogle Scholar
  33. 33.
    Kripke ML (1983) The effect of ultraviolet radiation on the immune system. In: Parrish JA (ed) A scientific round table. Johnson and Johnson Baby Products, New Brunswick, NJ, pp 87 –106Google Scholar
  34. 34.
    Daynes RA, Bernhard EJ, Gurish MF, Lynch DH (1981) Experimental photoimmunology: immunologic ramifications of UV-induced carcinogenesis. J Invest Dermatol 77:77 –85PubMedCrossRefGoogle Scholar
  35. 35.
    Gurish MF, Roberts LK, Krueger GG, Daynes RA (1981) The effect of various sunscreen agents on skin damage and the induction of tumor susceptibility in mice subjected to ultraviolet irradiation. J Invest Dermatol 76:246 –251PubMedCrossRefGoogle Scholar
  36. 36.
    Kripke ML (1982) The role of UVR-induced immunosup-pression in experimental photocarcinogenesis. Progr Derm 16:1Google Scholar
  37. 37.
    Kripke ML (1977) Latency, histology, and antigenicity of tumors induced by ultraviolet light in three inbred mouse strains. Cancer Res 37:1395 –1400PubMedGoogle Scholar
  38. 38.
    Kripke ML (1977) Ultraviolet radiation and tumor immunity. J Reticuloendothel Soc 22:217 –222PubMedGoogle Scholar
  39. 39.
    Kripke ML (1981) Immunologic mechanisms in UV radiation carcinogenesis. Adv Cancer Res 34:69 –106PubMedCrossRefGoogle Scholar
  40. 40.
    Kripke ML (1974) Antigenicity of murine skin tumors induced by ultraviolet light. J Natl Cancer Inst 53:1333 –1336PubMedGoogle Scholar
  41. 41.
    Kripke ML, Morison WL, Parrish JA (1981) Differences in the immunologic reactivity of mice treated with UVB or methoxsalen plus U VA radiation. J Invest Dermatol 76:445 –448PubMedCrossRefGoogle Scholar
  42. 42.
    Toews GB, Bergstresser PR, Streilein JW (1980) Epidermal langerhans cell density determines whether contact hyper-sensitivity or unresponsiveness follows skin painting with DNFB. J Immunol 124:445–453PubMedGoogle Scholar
  43. 43.
    Zelickson AS, Mottaz J (1970) The effect of sunlight on human epidermis. A quantitative electron microscopic study of dendritic cells. Arch Dermatol 101:312–315PubMedCrossRefGoogle Scholar
  44. 44.
    Rady P, Scinicariello F, Wagner RF Jr, Tyring SK (1992) p53 mutations in basal cell carcinomas. Cancer Res 52:3804–3806PubMedGoogle Scholar
  45. 45.
    Dicker T, Siller G, Saunders N (2002) Molecular and cellular biology of basal cell carcinoma. Australas J Dermatol 43:241–246PubMedCrossRefGoogle Scholar
  46. 46.
    Ouhtit A, Nakazawa H, Armstrong BK, Kricker A, Tan E, Yamasaki H, English DR (1998) UV-radiation-specific p53 mutation frequency in normal skin as a predictor of risk of basal cell carcinoma. J Natl Cancer Inst 90:523–531PubMedCrossRefGoogle Scholar
  47. 47.
    Cleaver JE (1969) Xeroderma pigmentosum: a human disease in which an initial stage of DNA repair is defective. Proc Natl Acad Sci USA 63:428–435PubMedCrossRefGoogle Scholar
  48. 48.
    Cleaver JE (1968) Defective repair replication of DNA in xeroderma pigmentosum. Nature 218:652–656PubMedCrossRefGoogle Scholar
  49. 49.
    Kraemer KH (1981) Cancer prone genodermatoses and DNA repair. Progr Derm 15:1Google Scholar
  50. 50.
    Lehmann AR, Kirk-Bell S, Arlett CF, Harcourt SA, de Weerd-Kastelein EA, Keijzer W, Hall-Smith P (1977) Repair of ultraviolet light damage in a variety of human fibroblast cell strains. Cancer Res 37:904–910PubMedGoogle Scholar
  51. 51.
    Gailani MR, Stahle-Backdahl M, Leffell DJ, Glynn M, Zaphiropoulos PG, Pressman C, Unden AB, Dean M, Brash DE, Bale AE, Toftgard R (1996) The role of the human homologue of Drosophila patched in sporadic basal cell carcinomas. Nat Genet 14:78–81PubMedCrossRefGoogle Scholar
  52. 52.
    ya-Grosjean L, Couve-Privat S (2005) Sonic hedgehog signaling in basal cell carcinomas. Cancer Lett 225:181–192CrossRefGoogle Scholar
  53. 53.
    Lacour JP (2002) Carcinogenesis of basal cell carcinomas: genetics and molecular mechanisms. Br J Dermatol 146(Suppl 61):17–19PubMedCrossRefGoogle Scholar
  54. 54.
    Kim MY, Park HJ, Baek SC, Byun DG, Houh D (2002) Mutations of the p53 and PTCH gene in basal cell carcinomas: UV mutation signature and strand bias. J Dermatol Sci 29:1–9PubMedCrossRefGoogle Scholar
  55. 55.
    Czarnecki D, Tait B, Nicholson I, Lewis A (1994) Multiple non-melanoma skin cancer: evidence that different MHC genes are associated with different cancers. Dermatology 188:88–90PubMedCrossRefGoogle Scholar
  56. 56.
    Kennedy C, Bajdik CD, Willemze R, Bouwes Bavinck JN (2005) Chemical exposures other than arsenic are probably not important risk factors for squamous cell carcinoma, basal cell carcinoma and malignant melanoma of the skin. Br J Dermatol 152:194–197PubMedCrossRefGoogle Scholar
  57. 57.
    Zak-Prelich M, Narbutt J, Sysa-Jedrzejowska A (2004) Environmental risk factors predisposing to the development of basal cell carcinoma. Dermatol Surg 30:248–252CrossRefGoogle Scholar
  58. 58.
    Hartevelt MM, Bavinck JN, Kootte AM, Vermeer BJ, Vandenbroucke JP (1990) Incidence of skin cancer after renal transplantation in The Netherlands. Transplantation 49:506–509PubMedCrossRefGoogle Scholar
  59. 59.
    Jensen P, Moller B, Hansen S (2000) Skin cancer in kidney and heart transplant recipients and different long-term immunosuppressive therapy regimens. J Am Acad Dermatol 42:307PubMedCrossRefGoogle Scholar
  60. 60.
    Webb MC, Compton F, Andrews PA, Koffman CG (1997) Skin tumours posttransplantation: a retrospective analysis of 28 years ' experience at a single centre. Transplant Proc 29:828 –830PubMedCrossRefGoogle Scholar
  61. 61.
    Kraemer KH, Lee MM, Andrews AD, Lambert WC (1994) The role of sunlight and DNA repair in melanoma and non-melanoma skin cancer. The xeroderma pigmentosum paradigm. Arch Dermatol 130:1018–1021PubMedCrossRefGoogle Scholar
  62. 62.
    Lindelof B, Sigurgeirsson B, Gabel H, Stern RS (2000) Incidence of skin cancer in 5356 patients following organ transplantation. Br J Dermatol 143:513–519PubMedGoogle Scholar
  63. 63.
    Ramachandran S, Fryer AA, Smith AG, Lear JT, Bowers B, Hartland AJ, Whiteside JR, Jones PW, Strange RC (2001) Basal cell carcinomas: association of allelic variants with a high-risk subgroup of patients with the multiple presentation phenotype. Pharmacogenetics 11:247–254PubMedCrossRefGoogle Scholar
  64. 64.
    Wei Q, Matanoski GM, Farmer ER, Hedayati MA, Grossman L (1995) DNA repair capacity for ultraviolet light-induced damage is reduced in peripheral lymphocytes from patients with basal cell carcinoma. J Invest Dermatol 104:933–936PubMedCrossRefGoogle Scholar
  65. 65.
    (1994) Guidelines of care for phototherapy and photochemo-therapy. American academy of dermatology committee on guidelines of care. J Am Acad Dermatol 31:643–648Google Scholar
  66. 66.
    Lear JT, Heagerty AH, Smith A, Bowers B, Payne CR, Smith CA, Jones PW, Gilford J, Yengi L, Alldersea J, Fryer AA, Strange RC (1996) Multiple cutaneous basal cell carcinomas: glutathione S-transferase (GSTM1, GSTT1) and cytochrome P450 (CYP2D6, CYP1A1) polymorphisms influence tumour numbers and accrual. Carcinogenesis 17:1891–1896PubMedCrossRefGoogle Scholar
  67. 67.
    Freeman RG, Duncan C (1973) Recurrent skin cancer. Arch Dermatol 107:395–399PubMedCrossRefGoogle Scholar
  68. 68.
    Popkin GL, Bart RS (1975) Excision versus curettage and electrodesiccation as dermatologic office procedures for the treatment of basal-cell carcinomas. J Dermatol Surg 1:33–35PubMedGoogle Scholar
  69. 69.
    Miller SJ, Alam M, Andersen J, Berg D, Bichakjian CK, Bowen G, Cheney RT, Glass F, Grekin RC, Grichnik JM, Kessinger A, Lee NY, Lessin S, Lydiatt DD, Margolis LW, Michalski J, Nehal KS, Nghiem P, Oseroff AR, Rosenberg EW, Shaha AR, Siegle RJ, Urist MM (2007) Basal cell and squamous cell skin cancers. J Natl Compr Canc Netw 5:506–529PubMedGoogle Scholar
  70. 70.
    Lang PG, Maize JC (2005) Basal Cell Carcinoma. In: Rigel DS, Friedman RJ, Dzubow LM, Reintgen DS, Bystryn JC, Marks R (eds) Cancer of the skin. Elsevier Saunders, PhiladelphiaGoogle Scholar
  71. 71.
    Spiller WF, Spiller RF (1984) Treatment of basal cell epithe-lioma by curettage and electrodesiccation. J Am Acad Dermatol 11:808–814PubMedCrossRefGoogle Scholar
  72. 72.
    Swanson NA (1983) Mohs surgery: technique, indications, applications, and the future. Archives of Dermatology 119:761–773PubMedCrossRefGoogle Scholar
  73. 73.
    Sweet RD (1983) The management of basal cell carcinoma by curettage. Br J Dermatol 75:137–148CrossRefGoogle Scholar
  74. 74.
    Knox J, Lyles TW, Shapiro EM, et al (1960) Curettage and electrodesiccation in the treatment of skin cancer. Arch Dermatol 82:197PubMedCrossRefGoogle Scholar
  75. 75.
    KNOX JM, Freeman RG, HEATON CL (1962) Curettage and electrodesiccation in the treatment of skin cancer. South Med J 55:1212 –1215PubMedCrossRefGoogle Scholar
  76. 76.
    Sloane JP (1977) The value of typing basal cell carcinomas in predicting recurrence after surgical excision. Br J Dermatol 96:127–132PubMedCrossRefGoogle Scholar
  77. 77.
    Kopf AW, Bart RS, Schrager D, Lazar M, Popkin GL (1977) Curettage-electrodesiccation treatment of basal cell carcinomas. Arch Dermatol 113:439–443PubMedCrossRefGoogle Scholar
  78. 78.
    Tromovitch TA (1965) Skin cancer; treatment by curettage and desiccation. Calif Med 103:107–108PubMedGoogle Scholar
  79. 79.
    McDaniel WE (1978) Surgical therapy for basal cell epithe-liomas by curettage only. Arch Dermatol 114:1491–1492PubMedCrossRefGoogle Scholar
  80. 80.
    McDaniel WE (1983) Therapy for basal cell epitheliomas by curettage only. Further study. Arch Dermatol 119:901–903PubMedCrossRefGoogle Scholar
  81. 81.
    Reymann F (1975) Multiple basal cell carcinomas of the skin. Treatment with curettage. Arch Dermatol 111:877–879PubMedCrossRefGoogle Scholar
  82. 82.
    Reymann F (1971) Treatment of basal cell carcinoma of the skin with curettage. Arch Dermatol 103:623–627PubMedCrossRefGoogle Scholar
  83. 83.
    Thissen MR, Neumann MH, Schouten LJ (1999) A systematic review of treatment modalities for primary basal cell carcinomas. Arch Dermatol 135:1177–1183PubMedCrossRefGoogle Scholar
  84. 84.
    Bisson MA, Dunkin CS, Suvarna SK, Griffiths RW (2002) Do plastic surgeons resect basal cell carcinomas too widely? A prospective study comparing surgical and histological margins. Br J Plast Surg 55:293–297PubMedCrossRefGoogle Scholar
  85. 85.
    Burg G, Hirsch RD, Konz B, Braun-Falco O (1975) Histographic surgery: accuracy of visual assessment of the margins of basal-cell epithelioma. J Dermatol Surg 1:21–24PubMedGoogle Scholar
  86. 86.
    Epstein E (1973) How accurate is the visual assessment of basal carcinoma margins? Br J Dermatol 89:37–43PubMedCrossRefGoogle Scholar
  87. 87.
    Hudson-Peacock MJ, Matthews JN, Lawrence CM (1995) Relation between size of skin excision, wound, and specimen. J Am Acad Dermatol 32:1010–1015CrossRefGoogle Scholar
  88. 88.
    Richmond JD, Davie RM (1987) The significance of incomplete excision in patients with basal cell carcinoma. Br J Plast Surg 40:63–67PubMedCrossRefGoogle Scholar
  89. 89.
    Roenigk RK, Ratz JL, Bailin PL, Wheeland RG (1986) Trends in the presentation and treatment of basal cell carcinomas. J Dermatol Surg Oncol 12:860–865PubMedGoogle Scholar
  90. 90.
    Ceilley RI, Del Rosso JQ (2006) Current modalities and new advances in the treatment of basal cell carcinoma. Int J Dermatol 45:489–498PubMedCrossRefGoogle Scholar
  91. 91.
    Silverman MK, Kopf AW, Gladstein AH, Bart RS, Grin CM, Levenstein MJ (1992) Recurrence rates of treated basal cell carcinomas. Part 4: X-ray therapy. J Dermatol Surg Oncol 18:549–554PubMedGoogle Scholar
  92. 92.
    Hunter RD (1985) The radiotherapy of malignant disease. 1st edition, In: Easson EC, Pointon RCS (eds) Skin. Springer, New York, NY, pp 135Google Scholar
  93. 93.
    Dubin N, Kopf AW (1983) Multivariate risk score for recurrence of cutaneous basal cell carcinomas. Arch Dermatol 119:373–377PubMedCrossRefGoogle Scholar
  94. 94.
    Horn M, Wolf P, Wulf HC, Warloe T, Fritsch C, Rhodes LE, Kaufmann R, de RM, Legat FJ, Stender IM, Soler AM, Wennberg AM, Wong GA, Larko O (2003) Topical methyl aminolaevulinate photodynamic therapy in patients with basal cell carcinoma prone to complications and poor cosmetic outcome with conventional treatment. Br J Dermatol 149:1242–1249PubMedCrossRefGoogle Scholar
  95. 95.
    Vinciullo C, Eliott T, Gebauer K, Spelman L, Ngyen R (2004) MAL-PDT in patients with basal cell carcinoma: results of an Australian multicenter study. International Skin Cancer ConferenceGoogle Scholar
  96. 96.
    Bassett-Seguin, Ibbotson S, Emtestam L, Tarstedt M, Morton C, Maroti M, et al (2004) MAL-PDT versus cryo-therapy in primary sBCC: results of 36 months follow-up. J Eur Acad Dermatol Venereol 18(Suppl 2):412Google Scholar
  97. 97.
    Bassett-Seguin N, Ibbotson S, Emtestam L, Tarstedt M, Morton C, Maroti M, et al (2005) MAL-PDT vs. cryother-apy in primary sBCC: results of 48 month follow-up. J Eur Acad Dermatol Venereol 19(Suppl 2):237Google Scholar
  98. 98.
    Wang I, Bendsoe N, Klinteberg CA, Enejder AM, nders-son-Engels S, Svanberg S, Svanberg K (2001) Photodynamic therapy vs. cryosurgery of basal cell carcinomas: results of a phase III clinical trial. Br J Dermatol 144:832–840PubMedCrossRefGoogle Scholar
  99. 99.
    Peng Q, Soler AM, Warloe T, Nesland JM, Giercksky KE (2001) Selective distribution of porphyrins in skin thick basal cell carcinoma after topical application of methyl 5-aminolevulinate. J Photochem Photobiol B 15:140–145CrossRefGoogle Scholar
  100. 100.
    Rhodes LE, de RM, Enstrom Y, Groves R, Morken T, Goulden V, Wong GA, Grob JJ, Varma S, Wolf P (2004) Photodynamic therapy using topical methyl aminolevulinate vs surgery for nodular basal cell carcinoma: results of a multicenter randomized prospective trial. Arch Dermatol 140:17–23PubMedCrossRefGoogle Scholar
  101. 101.
    Tope WD, Menter A, El-Azhary RA, Lowe NJ, Jarratt M, Pariser DM, et al (2004) Comparison of topical methyl aminolevulinate photodynamic therapy versus placebo photodynamic therapy in nodular BCC. J Eur Acad Dermatol Venereol 18(Suppl 2):13–14Google Scholar
  102. 102.
    Calzavara-Pinton PG (1995) Repetitive photodynamic therapy with topical delta-aminolaevulinic acid as an appropriate approach to the routine treatment of superficial non-melanoma skin tumours. J Photochem Photobiol B 29:53–57CrossRefGoogle Scholar
  103. 103.
    Svanberg K, Andersson T, Killander D, Wang I, Stenram U, ndersson-Engels S, Berg R, Johansson J, Svanberg S (1994) Photodynamic therapy of non-melanoma malignant tumours of the skin using topical delta-amino levulinic acid sensiti-zation and laser irradiation. Br J Dermatol 130:743–751PubMedCrossRefGoogle Scholar
  104. 104.
    Thissen MR, Schroeter CA, Neumann HA (2000) Photodynamic therapy with delta-aminolaevulinic acid for nodular basal cell carcinomas using a prior debulking technique. Br J Dermatol 142:338–339PubMedCrossRefGoogle Scholar
  105. 105.
    Soler AM, Warloe T, Tausjo J, Berner A (1999) Photodynamic therapy by topical aminolevulinic acid, dimethylsulphoxide and curettage in nodular basal cell carcinoma: a one-year follow-up study. Acta Derm Venereol 79:204–206PubMedCrossRefGoogle Scholar
  106. 106.
    Sacchini V, Lovo GF, Arioli N, Nava M, Bandieramonte G (1984) Carbon dioxide laser in scalp tumor surgery. Lasers Surg Med 4:261–269PubMedCrossRefGoogle Scholar
  107. 107.
    Wheeland RG, Bailin PL, Ratz JL, Roenigk RK (1987) Carbon dioxide laser vaporization and curettage in the treatment of large or multiple superficial basal cell carcinomas. J Dermatol Surg Oncol 13:119–125PubMedGoogle Scholar
  108. 108.
    Iyer S, Bowes L, Kricorian G, Friedli A, Fitzpatrick RE (2004) Treatment of basal cell carcinoma with the pulsed carbon dioxide laser: a retrospective analysis. Dermatol Surg 30:1214–1218PubMedCrossRefGoogle Scholar
  109. 109.
    Thomas DJ, King AR, Peat BG (2003) Excision margins for nonmelanotic skin cancer. Plast Reconstr Surg 112:57–63PubMedCrossRefGoogle Scholar
  110. 110.
    Walker P, Hill D (2006) Surgical treatment of basal cell carcinomas using standard postoperative histological assessment. Australas J Dermatol 47:1–12PubMedCrossRefGoogle Scholar
  111. 111.
    Wolf DJ, Zitelli JA (1987) Surgical margins for basal cell carcinoma. Arch Dermatol 123:340–344PubMedCrossRefGoogle Scholar
  112. 112.
    Marks R, Ainslie J, Bekhor P, Green A, Henderson M, Hill D (2002) Clinical practice guidelines non-melanoma skin cancer: guideline for treatment and management in Australia. 35–47. Commonwealth of Australia, CanberraGoogle Scholar
  113. 113.
    Miller SJ (2004) Basal cell and squamous cell skin cancers. Practice Guidelines in Oncology, National Comprehensive Cancer NetworkGoogle Scholar
  114. 114.
    Telfer NR, Colver GB, Bowers PW (1999) Guidelines for the management of basal cell carcinoma. British association of dermatologists. Br J Dermatol 141:415–423PubMedCrossRefGoogle Scholar
  115. 115.
    Sexton M, Jones DB, Maloney ME (1990) Histologic pattern analysis of basal cell carcinoma. Study of a series of 1039 consecutive neoplasms. J Am Acad Dermatol 23:1118–1126PubMedCrossRefGoogle Scholar
  116. 116.
    Breuninger H, Dietz K (1991) Prediction of subclinical tumor infiltration in basal cell carcinoma. J Dermatol Surg Oncol 17:574–578PubMedGoogle Scholar
  117. 117.
    Rowe DE, Carroll RJ, Day CL Jr (1989) Mohs surgery is the treatment of choice for recurrent (previously treated) basal cell carcinoma. J Dermatol Surg Oncol 15:424–431PubMedGoogle Scholar
  118. 118.
    Chiller K, Passaro D, McCalmont T, Vin-Christian K (2000) Efficacy of curettage before excision in clearing surgical margins of nonmelanoma skin cancer. Arch Dermatol 136:1327–1332PubMedCrossRefGoogle Scholar
  119. 119.
    Jiang SB. Mohs Surgery. eMedicine Web Site. 5–4–2007. 3–2–2008Google Scholar
  120. 120.
    Wennberg AM, Larko O, Stenquist B (1999) Five-year results of Mohs ' micrographic surgery for aggressive facial basal cell carcinoma in Sweden. Acta Derm Venereol 79:370–372PubMedCrossRefGoogle Scholar
  121. 121.
    Cook J, Zitelli JA (1998) Mohs micrographic surgery: a cost analysis. J Am Acad Dermatol 39:698–703PubMedCrossRefGoogle Scholar
  122. 122.
    Bath-Hextall F, Perkins W, Bong J, Williams H (2007) Interventions for basal cell carcinoma of the skin. Cochrane Database Syst Rev CD003412Google Scholar
  123. 123.
    Cornell RC, Greenway HT, Tucker SB, Edwards L, Ashworth S, Vance JC, Tanner DJ, Taylor EL, Smiles KA, Peets EA (1990) Intralesional interferon therapy for basal cell carcinoma. J Am Acad Dermatol 23:694–700PubMedCrossRefGoogle Scholar
  124. 124.
    Vine JE (2001) Skin cancer update. Treatment alternatives for basal-cell and squamous-cell carcinoma. N J Med 98:35–37PubMedGoogle Scholar
  125. 125.
    Ebner H (1970) Treatment of skin epitheliomas with 5-flu-orouracil (5-FU) ointment. Influence of therapeutic design on recurrence of lesions. Dermatologica 140:42–46PubMedCrossRefGoogle Scholar
  126. 126.
    Epstein E (1985) Fluorouracil paste treatment of thin basal cell carcinomas. Arch Dermatol 121:207–213PubMedCrossRefGoogle Scholar
  127. 127.
    Klostermann GF (1970) Effects of 5-fluorouracil (5-FU) ointment on normal and diseased skin. Histological find-ings and deep action. Dermatologica 140:47–54PubMedCrossRefGoogle Scholar
  128. 128.
    Gross K, Kircik L, Kricorian G (2007) 5 % 5-Fluorouracil cream for the treatment of small superficial Basal cell carcinoma: efficacy, tolerability, cosmetic outcome, and patient satisfaction. Dermatol Surg 33:433–439PubMedCrossRefGoogle Scholar
  129. 129.
    Cristofolini M, Zumiani G, Scappini P, Piscioli F (1984) Aromatic retinoid in the chemoprevention of the progression of nevoid basal-cell carcinoma syndrome. J Dermatol Surg Oncol 10:778–781PubMedGoogle Scholar
  130. 130.
    Hodak E, Ginzburg A, David M, Sandbank M (1987) Etretinate treatment of the nevoid basal cell carcinoma syndrome. Therapeutic and chemopreventive effect. Int J Dermatol 26:606–609PubMedCrossRefGoogle Scholar
  131. 131.
    Peck GL (1986) Topical tretinoin in actinic keratosis and basal cell carcinoma. J Am Acad Dermatol 15:829–835PubMedCrossRefGoogle Scholar
  132. 132.
    Peck GL, DiGiovanna JJ, Sarnoff DS, Gross EG, Butkus D, Olsen TG, Yoder FW (1988) Treatment and prevention of basal cell carcinoma with oral isotretinoin. J Am Acad Dermatol 19:176–185PubMedCrossRefGoogle Scholar
  133. 133.
    Stanley MA (2002) Imiquimod and the imidazoquinolo-nes: mechanism of action and therapeutic potential. Clin Exp Dermatol 27:571–577PubMedCrossRefGoogle Scholar
  134. 134.
    Geisse J, Caro I, Lindholm J, Golitz L, Stampone P, Owens M (2004) Imiquimod 5 % cream for the treatment of super-ficial basal cell carcinoma: results from two phase III, randomized, vehicle-controlled studies. J Am Acad Dermatol 50:722–733PubMedCrossRefGoogle Scholar
  135. 135.
    Geisse JK, Rich P, Pandya A, Gross K, Andres K, Ginkel A, Owens M (2002) Imiquimod 5 % cream for the treatment of superficial basal cell carcinoma: a double-blind, randomized, vehicle-controlled study. J Am Acad Dermatol 47:390–398PubMedCrossRefGoogle Scholar
  136. 136.
    Schulze HJ, Cribier B, Requena L, Reifenberger J, Ferrandiz C, Garcia DA, Tebbs V, McRae S (2005) Imiquimod 5 % cream for the treatment of superficial basal cell carcinoma: results from a randomized vehicle-controlled phase III study in Europe. Br J Dermatol 152:939–947PubMedCrossRefGoogle Scholar
  137. 137.
    Shumack S, Robinson J, Kossard S, Golitz L, Greenway H, Schroeter A, Andres K, Amies M, Owens M (2002) Efficacy of topical 5 % imiquimod cream for the treatment of nodular basal cell carcinoma: comparison of dosing regimens. Arch Dermatol 138:1165–1171PubMedCrossRefGoogle Scholar
  138. 138.
    Eigentler TK, Kamin A, Weide BM, Breuninger H, Caroli UM, Mohrle M, Radny P, Garbe C (2007) A phase III, randomized, open label study to evaluate the safety and effi-cacy of imiquimod 5 % cream applied thrice weekly for 8 and 12 weeks in the treatment of low-risk nodular basal cell carcinoma. J Am Acad Dermatol 57:616–621PubMedCrossRefGoogle Scholar
  139. 139.
    Wagstaff A, Perry C (2007) Topical Imiquimod: a review of its use in the management of anogenital warts, actinic keratoses, basal cell carcinoma, and other skin lesions. Adis Drug Evaluation 67:2187–2210Google Scholar
  140. 140.
    Neville JA, Williford PM, Jorizzo JL (2007) Pilot study using topical imiquimod 5 % cream in the treatment of nodular basal cell carcinoma after initial treatment with curettage. J Drugs Dermatol 6:910–914PubMedGoogle Scholar
  141. 141.
    Rigel D, Torres A, Ely H (2006) Effectiveness of curettage and 5 % imiquimod cream in the treatment of basal cell carcinoma: clinical and cosmetic evaluation. J Am Acad Dermatol 54:AB174CrossRefGoogle Scholar
  142. 142.
    Spencer JM (2006) Pilot study of imiquimod 5 % cream as adjunctive therapy to curettage and electrodesiccation for nodular basal cell carcinoma. Dermatol Surg 32:63–69PubMedCrossRefGoogle Scholar
  143. 143.
    Guthrie TH Jr, Porubsky ES, Luxenberg MN, Shah KJ, Wurtz KL, Watson PR (1990) Cisplatin-based chemotherapy in advanced basal and squamous cell carcinomas of the skin: results in 28 patients including 13 patients receiving multimodality therapy. J Clin Oncol 8:342–346PubMedGoogle Scholar
  144. 144.
    Coker DD, Elias EG, Viravathana T, McCrea E, Hafiz M (1983) Chemotherapy for metastatic basal cell carcinoma. Arch Dermatol 119:44–50PubMedCrossRefGoogle Scholar
  145. 145.
    Hartman R, Hartman S, Green N (1986) Long-term survival following bony metastases from basal cell carcinoma. Report of a case. Arch Dermatol 122:912–914PubMedCrossRefGoogle Scholar
  146. 146.
    Wieman TJ, Shively EH, Woodcock TM (1983) Responsiveness of metastatic basal-cell carcinoma to chemotherapy. A case report. Cancer 52:1583–1585PubMedCrossRefGoogle Scholar
  147. 147.
    Guthrie TH, Jr., McElveen LJ, Porubsky ES, Harmon JD (1985) Cisplatin and doxorubicin. An effective chemotherapy combination in the treatment of advanced basal cell and squamous carcinoma of the skin. Cancer 55:1629–1632PubMedCrossRefGoogle Scholar
  148. 148.
    Guthrie TH, Porubsky ES (1982) Successful systemic chemotherapy of advanced squamous and basal cell carcinoma of the skin with cis-diamminedichloroplatinum III and doxorubicin. Laryngoscope 92:1298–1299PubMedCrossRefGoogle Scholar
  149. 149.
    Robinson JK (1987) Use of a combination of chemotherapy and radiation therapy in the management of advanced basal cell carcinoma of the head and neck. J Am Acad Dermatol 17:770–774PubMedCrossRefGoogle Scholar
  150. 150.
    Marcil I, Stern RS (2000) Risk of developing a subsequent nonmelanoma skin cancer in patients with a history of non-melanoma skin cancer: a critical review of the literature and meta-analysis. Arch Dermatol 136:1524–1530PubMedCrossRefGoogle Scholar
  151. 151.
    Rowe DE, Carroll RJ, Day CL Jr (1989) Long-term recurrence rates in previously untreated (primary) basal cell carcinoma: implications for patient follow-up. J Dermatol Surg Oncol 15:315–328PubMedGoogle Scholar
  152. 152.
    Marghoob A, Kopf AW, Bart RS, Sanfilippo L, Silverman MK, Lee P, Levy E, Vossaert KA, Yadav S, Abadir M (1993) Risk of another basal cell carcinoma developing after treatment of a basal cell carcinoma. J Am Acad Dermatol 28:22–28PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 2010

Authors and Affiliations

  • Manisha J Patel
    • 1
    Email author
  • Phillip M Williford
  • Stephen Shumack
  1. 1.Department of DermatologyJohns Hopkins School of MedicineBaltimoreUSA

Personalised recommendations